ArticleFrontiers in immunology2025
PD-L1 expression and mismatch repair deficiency in locally advanced head and neck squamous cell carcinoma treated with chemoradiotherapy: association with treatment response and survival.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concurrent chemoradiotherapy (CCRT) served as the cornerstone of definitive treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC), yet there was heterogeneity in patients' treatment responses. This study aimed to evaluate the clinical significance of programmed death ligand-1 (PD-L1) expression and deficient mismatch repair (dMMR) as predictive markers of response to CCRT in patients with LA-HNSCC. Methods: This study retrospectively analyzed 156 cases of LA-HNSCC patients who received CCRT treatment at our hospital from January 2020 to April 2024. All patients received intensity-modulated radiotherapy with concurrent chemotherapy. PD-L1 expression was assessed using immunohistochemistry and quantified with the Combined Positive Score (CPS). Mismatch repair status was evaluated using antibodies against MLH1, PMS2, MSH2, and MSH6. The treatment response was assessed according to the Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1). Results: This study included a total of 156 patients with LA-HNSCC, with a male predominance (125 cases). The deficient mismatch repair (dMMR) prevalence was 6.4% (10/156), and high PD-L1 expression (CPS≥20) was observed in 47.4% (74/156) of patients. There was a significant association between high PD-L1 expression and an increased objective response rate to CCRT (97.1% compared to 58.5%, P<0.001). Conversely, patients with dMMR exhibited a reduced response rate (50.0% versus 79.5%, P = 0.031). In the survival analysis, patients with high PD-L1 expression demonstrated significantly longer overall survival (OS) (P = 0.0021) and progression-free survival (PFS) (P<0.001). In contrast, dMMR status was not significantly associated with OS or PFS. Multivariate analysis identified smoking (HR = 6.871, 95%CI: 2.214-21.32, P<0.001) and high PD-L1 expression (HR = 2.591, 95%CI: 1.036-6.483, P = 0.042) as independent risk factors for OS. Conclusion: The study confirmed that high PD-L1 expression was a positive biomarker for predicting the benefit of CCRT in patients with LA-HNSCC. Although dMMR was associated with initial treatment resistance, its unique immunogenicity was found to influence disease progression and subsequent treatment options. These findings suggested that MMR testing in LA-HNSCC patients had significant clinical value, not only aiding in the identification of patients who might benefit from subsequent immunotherapy but also potentially informing initial treatment strategies, such as the prospective exploration of combined immunotherapy approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.